• Rigel Pharmaceuticals Inc RIGL.OQ reported quarterly adjusted earnings of 63 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -50 cents. The mean expectation of six analysts for the quarter was for earnings of 2 cents per share. Wall Street expected results to range from -8 cents to 14 cents per share.

• Revenue rose 80.6% to $53.33 million from a year ago; analysts expected $43.87 million.

• Rigel Pharmaceuticals Inc's reported EPS for the quarter was 63 cents​.

• The company reported quarterly net income of $11.45 million.

• Rigel Pharmaceuticals Inc shares had risen by 6.2% this quarter and gained 13.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 89.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is "hold."

• Wall Street's median 12-month price target for Rigel Pharmaceuticals Inc is $23.50

This summary was machine generated from LSEG data May 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)